Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Innate to receive $5M milestone payment from AstraZeneca
The plan is to advance innovative therapies to drug-resistant cancers
An estimated 21 million American women experience BV
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
